1119 related articles for article (PubMed ID: 32528145)
1. RAS-targeted therapies: is the undruggable drugged?
Moore AR; Rosenberg SC; McCormick F; Malek S
Nat Rev Drug Discov; 2020 Aug; 19(8):533-552. PubMed ID: 32528145
[TBL] [Abstract][Full Text] [Related]
2. Drugging the Undruggable: Advances on RAS Targeting in Cancer.
Molina-Arcas M; Samani A; Downward J
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34200676
[TBL] [Abstract][Full Text] [Related]
3. Drugging K-Ras
Ni D; Li X; He X; Zhang H; Zhang J; Lu S
Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in cancer drug discovery targeting RAS.
Wilson CY; Tolias P
Drug Discov Today; 2016 Dec; 21(12):1915-1919. PubMed ID: 27506872
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of RAS: proven and potential vulnerabilities.
Zuberi M; Khan I; O'Bryan JP
Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
[TBL] [Abstract][Full Text] [Related]
6. Drugging RAS: Know the enemy.
Papke B; Der CJ
Science; 2017 Mar; 355(6330):1158-1163. PubMed ID: 28302824
[TBL] [Abstract][Full Text] [Related]
7. Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.
Coley AB; Ward A; Keeton AB; Chen X; Maxuitenko Y; Prakash A; Li F; Foote JB; Buchsbaum DJ; Piazza GA
Adv Cancer Res; 2022; 153():131-168. PubMed ID: 35101229
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological targeting of RAS: Recent success with direct inhibitors.
O'Bryan JP
Pharmacol Res; 2019 Jan; 139():503-511. PubMed ID: 30366101
[TBL] [Abstract][Full Text] [Related]
9. Drugging all RAS isoforms with one pocket.
Kessler D; Bergner A; Böttcher J; Fischer G; Döbel S; Hinkel M; Müllauer B; Weiss-Puxbaum A; McConnell DB
Future Med Chem; 2020 Nov; 12(21):1911-1923. PubMed ID: 32779487
[TBL] [Abstract][Full Text] [Related]
10. Small molecular inhibitors for KRAS-mutant cancers.
Wu X; Song W; Cheng C; Liu Z; Li X; Cui Y; Gao Y; Li D
Front Immunol; 2023; 14():1223433. PubMed ID: 37662925
[TBL] [Abstract][Full Text] [Related]
11. Probing RAS Function with Monobodies.
Khan I; O'Bryan JP
Methods Mol Biol; 2021; 2262():281-302. PubMed ID: 33977484
[TBL] [Abstract][Full Text] [Related]
12. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
13. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategies to target RAS-mutant cancers.
Ryan MB; Corcoran RB
Nat Rev Clin Oncol; 2018 Nov; 15(11):709-720. PubMed ID: 30275515
[TBL] [Abstract][Full Text] [Related]
15. Ras and exosome signaling.
Sexton RE; Mpilla G; Kim S; Philip PA; Azmi AS
Semin Cancer Biol; 2019 Feb; 54():131-137. PubMed ID: 30769101
[TBL] [Abstract][Full Text] [Related]
16. Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.
Huynh MV; Campbell SL
Mini Rev Med Chem; 2016; 16(5):383-90. PubMed ID: 26423694
[TBL] [Abstract][Full Text] [Related]
17. Emerging strategies to target RAS signaling in human cancer therapy.
Chen K; Zhang Y; Qian L; Wang P
J Hematol Oncol; 2021 Jul; 14(1):116. PubMed ID: 34301278
[TBL] [Abstract][Full Text] [Related]
18. Targeting K-Ras Mutations Show Promise Towards Ending Ras's "Undruggable" Era.
Adams PD; Muhoza D
Protein Pept Lett; 2022; 29(12):1007-1015. PubMed ID: 36200189
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial strategies to target RAS-driven cancers.
Perurena N; Situ L; Cichowski K
Nat Rev Cancer; 2024 May; 24(5):316-337. PubMed ID: 38627557
[TBL] [Abstract][Full Text] [Related]
20. The Endeavours in RAS Inhibition - the Past, Present, and Future.
Hussain J; Kirubakaran S; Ravi S
Curr Top Med Chem; 2020; 20(29):2708-2722. PubMed ID: 32885752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
